级联激活的免疫细胞联合化疗治疗晚期非小细胞肺癌预后探讨

Prognosis of Cascade Activated Immune Cells Combined with Chemotherapy in the Treatment of Advanced Non-small-cell Lung Cancer

目的比分析晚期非小细胞肺癌(NSCLC)应用级联激活的免疫细胞(CAPRI)与化疗联合治疗对预后的影响效果。方法选择2015年5月-2019年5月民权县人民医院收治的晚期NSCLC患者70例作为研究对象,以随机双盲法分为两组,对照组用化疗方案,观察组则用CAPRI联合化疗方案。评价两组效果,记录中位生存时间与不良反应,检测治疗前后免疫功能指标,并比较。结果观察组临床受益率明显更高,与对照组差异显著(P<0.05);治疗前组间CD3^+、CD4^+、CD3^+/CD8^+对比无显著差异(P>0.05),治疗后观察组均明显高于对照组(P<0.05);两组均有不良反应,但对比无显著差异(P>0.05);观察组中位生存时间明显更长,与对照组差异显著(P<0.05)。结论晚期NSCLC患者化疗治疗基础上加用CAPRI联合治疗,不仅可以提高临床效果,延长中位生存时间,而且可以更好地改善患者的免疫功能,并不会显著增加不良反应,值得应用。

Objective To analyze the effect of cascade activated immune cells(CAPRI)combined with chemotherapy on prognosis of advanced non-small cell lung cancer(NSCLC).Methods 70 patients with advanced NSCLC admitted to our hospital from May 2015 to May 2019 were selected as the study subjects.All patients were divided into two groups by randomized double-blind method,the control group was treated with chemotherapy,and the observation group was treated with CAPRI combined with chemotherapy.The effects of the two groups were evaluated,median survival time and adverse reactions were recorded,and immune function indexes before and after treatment were measured and compared.Results The clinical benefit rate of the observation group was significantly higher than that of the control group(P<0.05).Before treatment,there was no significant difference between groups about CD3^+,CD4^+,CD3^+/CD8^+(P>0.05).However,after treatment,the observation group was significantly higher than the control group(P<0.05).Adverse reactions were found in both groups,but there was no significant difference(P>0.05).The median survival time of the observation group was significantly longer than that of the control group(P<0.05).Conclusion CAPRI combined chemotherapy for advanced NSCLC patients can not only improve the clinical effect and prolong the median survival time,but also better improve the immune function of patients without significantly increasing adverse reactions,which is worthy of application.